BRADLEY PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Signs
● 1 severe● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 11, 2006
- NT 10-K/Amissed a reporting deadline ↗Mar 15, 2006
- NT 10-Kmissed a reporting deadline ↗Mar 13, 2006
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2005
- NT 10-Qmissed a reporting deadline ↗Aug 9, 2005
- NT 11-Kmissed a reporting deadline ↗Jun 30, 2005
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-06-20Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Phase 4Recruitingreadout ~2026-08-01Adaptions and Resiliency to Multi-Stressor OpeRations
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Glassman DanielOfficer — Pres. & CEO | Feb 21, 2008 | D | 325,366 | $20.00 |
| Hamot Seth WDirector | Feb 21, 2008 | D | 33,000 | $20.00 |
| Landau Ralph NOfficer — VP - Manufacturing | Feb 21, 2008 | D | 15,000 | $9.97 |
| Goldstein Alan SOfficer — VP - Corporate Development | Feb 21, 2008 | D | 30,000 | $13.41 |
| Linton DouglasDirector | Feb 21, 2008 | D | 15,000 | $18.96 |
| Murphy William JDirector | Feb 21, 2008 | D | 15,000 | $11.58 |
| Glassman BradleyOfficer — Senior VP - Sales & Marketing | Feb 21, 2008 | D | 100,000 | $13.41 |
| Kriegsman Steven ADirector | Feb 21, 2008 | D | 5,000 | $12.40 |
| Fedida Michael JDirector | Feb 21, 2008 | D | 5,000 | $12.40 |
| Lenczycki R BrentOfficer — VP - CFO | Feb 21, 2008 | D | 15,000 | $2.00 |
| Fedida Andre DrDirector | Feb 21, 2008 | D | 5,000 | $12.40 |
| Glassman BradleyOfficer — Senior VP - Sales & Marketing | May 24, 2007 | Option exercise | 30,000 | $7.05 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 21, 2008
- Other material eventDec 14, 2007
- Other material eventDec 5, 2007
- Other material eventNov 29, 2007
- Results of operationsNov 8, 2007
- Entered a material agreement · Change in controlOct 30, 2007
- Entered a material agreementOct 10, 2007
- Entered a material agreementSep 4, 2007
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASCHEDULE 13GFeb 9, 2009
- 25-NSEFeb 26, 2008
- SC TO-I/AFeb 21, 2008
- 8-KCURRENT REPORTFeb 21, 2008
- S-8 POSFeb 21, 2008
- S-8 POSFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008
- 4PRIMARY DOCUMENTFeb 21, 2008